@article{Sun2018, 
author = {Boyang Sun and Robert M. Straubinger and Jonathan F. Lovell},
title = {Current taxane formulations and emerging cabazitaxel delivery systems},
year = {2018},
journal = {Nano Research},
volume = {11},
number = {10},
pages = {5193-5218},
keywords = {cabazitaxel, Jevtana®, taxanes, drug delivery systems, nanocarriers},
url = {https://www.sciopen.com/article/10.1007/s12274-018-2171-0},
doi = {10.1007/s12274-018-2171-0},
abstract = {Cabazitaxel is a second-generation taxane with promising anti-tumor activity and is approved for treating hormone-refractory metastatic prostate cancer previously treated with docetaxel. Although first-generation taxanes (i.e. paclitaxel and docetaxel) have sparked broad interest in a variety of drug delivery vehicles, fewer have yet been developed for cabazitaxel. This review summarizes several clinical-stage approaches for taxane formulation and recent efforts to develop novel cabazitaxel delivery systems.}
}